cisapride (Propulsid) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Cisapride is chemically related to metoclopramide, but unlike metoclopramide, it does not cross the blood-brain barrier or have antidopaminergic effects. Cisapride is a serotonin-4 (5-HT4) receptor agonist. Cisapride was indicated for the symptomatic treatment of adult patients with nocturnal heartburn due to gastroesophageal reflux disease. The Food and Drug Administration (FDA) in America stopped the marketing of cisapride as of 14th July 2000. They had received at least 341 reports of heart rhythm abnormalities and these led to 80 deaths. Other reported adverse effects are: headache, diarrhea, abdominal pain, nausea, constipation. Cisapride for animals has been found helpful in some cases of megaesophagus and is a common treatment for feline megacolon. Clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride. Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.   NCATS

Chemistry

  • SMILES: COC1CN(CCCOc2ccc(F)cc2)CCC1NC(=O)c3cc(Cl)c(N)cc3OC
  • InChIKey: DCSUBABJRXZOMT-UHFFFAOYSA-N
  • Mol. Mass: 465.95
  • ALogP: 3.36
  • ChEMBL Molecules:
    cisapride  
    cisapride  
    troleandomycin  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Discontinued
  • Delivery Methods: Oral
  • Pro Drug: No

Alternative names

4-amino-5-chloro-n-(1-(3-(4-fluorophenoxy)propyl)-3-methoxypiperidin-4-yl)-2-methoxybenzamide | 4-amino-5-chloro-n-{1-[3-(4-fluoro-phenoxy)-propyl]-3-methoxy-piperidin-4-yl}-2-methoxy-benzamide | acenalin | alimix | cipril | cis-4-amino-5-chloro-n-{1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl}-2-methoxybenzamide | cis-4-amino-5-chloro-n-{1-[3-(p-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl}-o-anisamide | cis-4-amino-5-chloro-n-(1-(3-(p-fluorophenoxy)propyl)-3-methoxy-4-piperidyl)-o-anisamide | cisaprid | cisaprida | cisapride | (+-)-cisapride | cisapride monohydrate | cisapridum | coordinax | prepulsid | prepulsid quicklet | propulsid | propulsid quicksolv | r51619 | r 51619 | r-51619 | risamal

Organizations (1)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (8)

Approved Indications (1)


 

Heartburn (approved 1993)

Experimental Indications - Clinical Trial Phases 1-4 (7)


 

Constipation ()

Diabetes Mellitus (Phase 4)

Gastroesophageal Reflux (Phase 4)

Gastroparesis (Phase 4)

Infant, Newborn (Phase 4)

Infant, Premature (Phase 4)

Megacolon ()

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue